Purpose. With a retrospective study at a single institution, we propose to
analyze the prognosis factors and adjuvant treatment for uterine sarcomas.
Materials and Methods: From 1975 to 1995, 73 uterine sarcomas were treated
at the Institut Curie, corresponding to 61 T1, 5 T2, and 8 T4 tumors. Thirt
een patients had metastatic disease at the rime of diagnosis. The mean age
was 58 years. In 71% of patients, the presenting sign was bleeding. This se
ries consisted of 44% leiomyosarcomas (LIMS), 19% endometrial stromal sarco
mas (ESS), and 31% carcinosarcomas or mixed mesodermal sarcomas (MMS). For
the grading classification, we used the classification of the Sarcoma Group
of the French Federation of Cancer Centres for soft tissue sarcomas. Of th
e patients, 66% presented a high-grade tumor.
Results. The median overall survival was 42 months, with a 5-year survival
of 45%. Histological grade, FIGO stage, histology types, and menopausal sta
tus were the four independent factors in multivariate analysis. Eighteen pa
tients relapsed locally (25.7%), with 77% central pelvic sites. Patients wi
th radiotherapy and ESS had better local control in multivariate analysis.
Thirty-four patients developed metastases (48.6%), mainly pulmonary (58.8%)
, Eight patients presented with peritoneal disease. High grades and LMS had
the worst survival without metastasis in multivariate analysis.
Conclusion: This study validated our classification for sarcoma grading and
confirmed the finding of worst prognosis for LMS and the importance of rad
iotherapy in local control. (C) 1999 Academic Press.